Clinical Trials Logo

Clinical Trial Summary

The endothelin receptor antagonist macitentan showed significant improvement compared with placebo in pulmonary vascular resistance (PVR) and 6-minute walking distance (6MWD) in inoperable CTEPH patients in the phase II MERIT-1 trial (AC-055E201, NCT02021292). However, in the MERIT-1 trial Japanese patients were not included. Therefore, in line with Japan's medical environment, this phase III study is to confirm the efficacy and safety of macitentan in Japanese CTEPH patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03809650
Study type Interventional
Source Actelion
Contact
Status Terminated
Phase Phase 3
Start date January 8, 2019
Completion date June 29, 2020

See also
  Status Clinical Trial Phase
Completed NCT03719027 - Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism : (Preva-CTEPH) N/A
Completed NCT02429284 - U.S. CTEPH Registry